Compare Costco Wholesale Corporation (COST) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs DexCom, Inc. — how do they compare? Costco Wholesale Corporation trades at $925.24 (market cap $408.78B), while DexCom, Inc. trades at $73.95 (market cap $28.60B). The key difference: Costco Wholesale Corporation is far larger — about 14.3× DexCom, Inc.'s market cap, and Costco Wholesale Corporation pays a 0.64% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| COST | DXCM | |
|---|---|---|
Market Cap | $408.78B | $28.60B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $89.53 |
52-Week Low | $849.63 | $54.84 |
Enterprise Value | $396.92B | $27.57B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $920.54, down 0.64% on the day, with a bearish technical signal from moving averages. The company reported revenue of $275.24 billion in 2025, with net income of $8.10 billion, and recently announced strong March sales growth of 11.3% year-over-year (GlobeNewsWire, 2026-04-08). Analyst consensus is strongly bullish with a $1,120 price target, supported by 38 buy ratings.
The stock's high P/E of 46.37 reflects premium valuation, but consistent revenue growth and membership fee increases underpin fundamentals. Risks include competitive pressures and sensitivity to consumer spending. Upside potential exists if the stock pulls back toward support levels, aligning with analyst targets.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
